Navigation Links
InterMune Reports First Quarter 2009 Financial Results and Business Highlights
Date:4/30/2009

after the call.

To access the webcast, please log on to the company's website at www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

The teleconference replay will be available approximately three hours after the call. The teleconference replay will be available for 10 business days following the call and can be accessed by dialing 800-642-1687 (U.S.) or 706-645-9291 (international), and entering the conference ID# 95970767. The webcast will remain available on the company's website until the next earnings call.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has an R&D portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes pirfenidone for which a Phase 3 program in patients with IPF (CAPACITY) has been completed and the compound is currently in the pre-registration stage. The company also has a research program focused on a pirfenidone analog named ITMN-520. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) expected to enter Phase 2b in the summer of 2009 and a second-generation HCV protease inhibitor research program. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without lim
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. InterMune to Release First Quarter Financial Results on April 30
2. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
3. InterMune to Present at Canaccord Adams Hepatitis C Conference
4. InterMune to Present at Citis 4th Annual Biotech Day
5. InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
6. InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
7. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
8. InterMune Announces Issuance of U.S. Patent for ITMN-191
9. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
10. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
11. InterMune to Present at J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... the globe, ISN improves the efficiency and effectiveness of contractor management systems. ISN,s online ... contractors in over 80 countries. ... ... Over 60,000 Worldwide Customers In More Than 80 Countries ... in Dallas, TX , ISN has additional offices in Calgary ...
(Date:7/30/2015)... Bedford, NH (PRWEB) , ... July 30, 2015 ... ... efficiency homogenizer for advanced fluid applications and designed for continuous operation up to ... clean-in-place and sterilization-in-place, ensuring safety, efficiency, and preventing toxic contamination. , The Pony™ ...
(Date:7/29/2015)... Asia-Pacific / Japan (Q2 2015: +14% CER ... 2015 on high-single-digit growth in China , as well as ... . Europe / Middle East ... of sales) showed gains in Germany , Turkey ... 2015: +4% CER / 49% of sales) grew 11%, excluding U.S. HPV sales, ...
(Date:7/29/2015)... , July 29, 2015 ... announced the addition of the "Global Biosimilars ... offering. The Global Biosimilars Market, 2015 ... the rapidly growing biosimilars market. With the blockbuster ... to minimize costs, biosimilars are being viewed as ...
Breaking Biology Technology:ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2QIAGEN Reports Results for Second Quarter and First Half of 2015 2QIAGEN Reports Results for Second Quarter and First Half of 2015 3QIAGEN Reports Results for Second Quarter and First Half of 2015 4QIAGEN Reports Results for Second Quarter and First Half of 2015 5QIAGEN Reports Results for Second Quarter and First Half of 2015 6QIAGEN Reports Results for Second Quarter and First Half of 2015 7QIAGEN Reports Results for Second Quarter and First Half of 2015 8QIAGEN Reports Results for Second Quarter and First Half of 2015 9QIAGEN Reports Results for Second Quarter and First Half of 2015 10Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 3
... March 11 Nile Therapeutics,Inc. (OTC Bulletin Board: NILT), ... year financial results for 2007 after the market,closes on ... conference,call and live webcast to discuss these financial results ... at 4:30 p.m. ET, 1:30 p.m. PT,that afternoon., ...
... NORCROSS, Ga., March 11 Immucor, Inc., ... to the,blood transfusion industry, announced today that ... BioArray Solutions Ltd., a privately held company,based ... development of molecular,diagnostic systems which enable rapid ...
... Boston Scientific,Corporation (NYSE: BSX ) is scheduled to ... being held March 18 - 20 in Miami,Florida., ... on Tuesday, March 18, beginning at approximately 9:00 a.m.,E.T. ... will,join Mr. LaViolette in a question and answer session., ...
Cached Biology Technology:Nile Therapeutics to Announce 2007 Fourth Quarter and Full Year Financial Results on Thursday, March 13, 2008 2Immucor To Acquire BioArray Solutions Ltd. 2Immucor To Acquire BioArray Solutions Ltd. 3Immucor To Acquire BioArray Solutions Ltd. 4
(Date:7/20/2015)... 2015  Acuity Market Intelligence,s latest research "The ... Commerce and Privacy" forecasts that between 2014 and ... be downloaded to smart mobile devices by 2.2 ... is projected to generate more than $67.9 billion ... forecast period.    "Biometrics is at ...
(Date:7/9/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), a leading ... will report financial results for the fourth quarter and ... the close of market. The company will host a ... p.m. PT (5:00 p.m. ET), during which management may ... the live call, analysts and investors should dial 888-455-2260 ...
(Date:7/9/2015)... , July 9, 2015  Synaptics ... developer of human interface solutions, today announced ... industry,s first fully hardware encapsulated fingerprint sensor ... authentication technology is literally off the grid, ... biometric matching within the fingerprint sensor to ...
Breaking Biology News(10 mins):Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3
... June 16-19, 2013 at the Best Western Ramkota Rapid City ... the Entomological Society of America,s North Central Branch holds its ... Forests pests, such as the mountain pine beetle ... such as the western corn rootworm, the soybean aphid, and ...
... duck genome consortium, consisted of scientists from China Agricultural ... completed the genome sequencing and analysis of the duck ... influenza A viruses, which caused a new epidemic in ... conclusions and provides an invaluable resource for unraveling the ...
... just published findings that explain a previously unknown ... another. The research significantly contributes to understanding why ... children and adults may develop life-threatening diseases. ... Professor Lars Allan Larsen (Department of Cellular and ...
Cached Biology News:The duck genome provides new insight into fighting bird flu 2Danish researchers expose new cause of life-threatening disease 2
...
... GeneSwitch Cell Lines stably express the ... cell line is functionally tested for ... the expression control vector pGene/V5-His/lacZ and ... treatment with mifepristone (Figure 1). These ...
... for 10 separate biopanning experiments, complexity ... gIII Sequencing Primer (100 pmol), for ... Primer (100 pmol), for automated DNA ... Control target (Streptavidin) and Elutant (Biotin), ...
... Materials for 15-20 enhancements when used as ... Blot Signal Enhancement System is designed to amplify the ... excellent tool for evaluating proteins with low expression., ... membrane prior to blocking the membrane; 1x solution; 250 ...
Biology Products: